Eisai and Biogen Report the Health Canada Acceptance of New Drug Submission for Leqembi (lecanemab) to Treat Early Alzheimer's Disease
Shots:
- Health Canada has accepted an NDS for lecanemab to treat patients with early Alzheimer's disease with confirmed amyloid pathology in the brain. The submission was based on the P-III study (Clarity AD) & the P-IIb study (Study 201) evaluating lecanemab in 856 & 1795 patients
- The results showed a reduction of clinical decline in early AD & the P-III study met its 1EPs & 2EPs with highly significant results. The (Clarity AD) study results were presented at CTAD 2022 & published in the NEJM
- Lecanemab, a humanized IgG1 mAb directed against aggregated soluble and insoluble forms of amyloid-beta. The therapy is designed to slow down the progression of the disease & have an effect on disease pathology
Ref: EISAI | Image: EISAI
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
